年龄相关性黄斑变性各阶段的人血浆代谢组学研究识别潜在脂质生物标志物
该横断面观察性研究前瞻性招募90例年龄相关性黄斑变性(AMD)患者(早期、中期、晚期各30例)和30例无玻璃体视网膜疾病的对照(>50岁),采用超高效液相色谱-高分辨质谱检测血浆代谢物。共鉴定878种生化物质,多变量逻辑回归发现87种代谢物在AMD患者与对照间水平显著不同,其中82.8%(n=72)属于脂质通路;方差分析显示87种中有48种(55.2%)在不同AMD分期之间也显著不同,甘油磷脂通路显著富集(P=4.7×10⁻⁹)。
要点
- AMD患者与对照相比有87种血浆代谢物水平显著不同,其中82.8%(n=72)属于脂质通路。
- 87种代谢物中有48种(55.2%)在不同AMD分期之间也显著不同。
- 甘油磷脂通路在差异代谢物中显著富集(P=4.7×10⁻⁹)。
核心结论
- AMD患者与对照相比血浆代谢组学谱发生改变,数据提示最显著的代谢物映射于甘油磷脂通路。
- 这些发现可能有助于增进对AMD发病机制的理解、支持开发基于血浆的AMD代谢组学生物标志物,并识别治疗该致盲性疾病的新靶点。
研究设计与样本
- 横断面观察性研究,前瞻性招募AMD患者和>50岁无玻璃体视网膜疾病的对照。
- 所有参与者接受彩色眼底照相,依据年龄相关性眼病研究分类方案进行AMD诊断和分期。
- 采集空腹血样,由Metabolon公司(美国北卡罗来纳州达勒姆)采用超高效液相色谱(UPLC)和高分辨质谱(MS)分析血浆。
- 采用主成分分析和多变量回归评估AMD患者与对照的代谢组学谱差异,并控制潜在混杂因素;使用MetaboAnalyst对显著代谢物进行通路富集分析以作生物学解释。
- 共纳入90例AMD患者(早期、中期、晚期各30例)和30例对照。
主要发现
- 采用UPLC和MS共鉴定878种生化物质。
- 多变量逻辑回归识别出87种代谢物在AMD患者与对照之间水平显著不同。
- 87种代谢物中82.8%(n=72)属于脂质通路,包括最显著的代谢物。
- 方差分析显示87种代谢物中有48种(55.2%)在不同AMD分期之间也显著不同。
- 这些代谢物中甘油磷脂通路显著富集(P=4.7×10⁻⁹)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize the plasma metabolomic profile of patients with age-related macular degeneration (AMD) using mass spectrometry (MS). DESIGN: Cross-sectional observational study. PARTICIPANTS: We prospectively recruited participants with a diagnosis of AMD and a control group (>50 years of age) without any vitreoretinal disease. METHODS: All participants underwent color fundus photography, used for AMD diagnosis and staging, according to the Age-Related Eye Disease Study classification scheme. Fasting blood samples were collected and plasma was analyzed by Metabolon, Inc. (Durham, NC), using ultrahigh-performance liquid chromatography (UPLC) and high-resolution MS. Metabolon's hardware and software were used to identify peaks and control quality. Principal component analysis and multivariate regression were performed to assess differences in the metabolomic profiles of AMD patients versus controls, while controlling for potential confounders. For biological interpretation, pathway enrichment analysis of significant metabolites was performed using MetaboAnalyst. MAIN OUTCOME MEASURES: The primary outcome measures were levels of plasma metabolites in participants with AMD compared with controls and among different AMD severity stages. RESULTS: We included 90 participants with AMD (30 with early AMD, 30 with intermediate AMD, and 30 with late AMD) and 30 controls. Using UPLC and MS, 878 biochemicals were identified. Multivariate logistic regression identified 87 metabolites with levels that differed significantly between AMD patients and controls. Most of these metabolites (82.8%; n = 72), including the most significant metabolites, belonged to the lipid pathways. Analysis of variance revealed that of the 87 metabolites, 48 (55.2%) also were significantly different across the different stages of AMD. A significant enrichment of the glycerophospholipids pathway was identified (P = 4.7 × 10-9) among these metabolites. CONCLUSIONS: Participants with AMD have altered plasma metabolomic profiles compared with controls. Our data suggest that the most significant metabolites map to the glycerophospholipid pathway. These findings have the potential to improve our understanding of AMD pathogenesis, to support the development of plasma-based metabolomics biomarkers of AMD, and to identify novel targets for treatment of this blinding disease.
引用
- Laíns I, Kelly RS, Miller JB, et al. Human Plasma Metabolomics Study across All Stages of Age-Related Macular Degeneration Identifies Potential Lipid Biomarkers. Ophthalmology. 2017. PMID: 28916333. doi:10.1016/j.ophtha.2017.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。